Water
Active ingredient
Sold as ULINE Eyewash · NUWIQ · Bach Original Flower…
- Drug class
- -
- Availability
- Over-the-counter
- Routes
- Intravenous, Intramuscular, Subcutaneous, Intraperitoneal, Irrigation
- Markets covered
- 3
- Products on record
- 35
- FDA reports (12 mo)
- 1,284
Overview
Plain-language summary, compiled from the cited regulatory records
Water is an active ingredient used in products for ophthalmic use [1]. It is approved to wash the eye to help relieve irritation, stinging, discomfort, itching, and burning [1]. This is achieved by removing loose foreign material, air pollutants such as smog or pollen, and chlorinated water [1].
Products containing water as an active ingredient are available under various brand names, including Bach Original Flower Remedies and ULINE Eyewash [1]. In the past 12 months, there have been 1284 adverse event reports associated with these products [2]. The most frequently reported adverse events include myelosuppression, nausea, off-label use, dyspnea, and the drug being ineffective [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 16 | January 8, 2026 |
| US United States | FDA | 10 | April 11, 2026 |
| GB United Kingdom | MHRA | 9 | May 22, 2026 |
CACanada· Health Canada
16 products
Uses
Sterile Water for Injection USP is indicated for use in adults and pediatric patients as a diluent or solvent in the aseptic preparation of parenteral solutions or as a vehicle for drug administration.
How to take
USUnited States· FDA
10 products
Uses
Uses washes the eye to help relieve • irritation • stinging • discomfort • itching • burning by removing • loose foreign material • air pollutants (smog or pollen) • chlorinated water
How to take
GBUnited Kingdom· MHRA
9 products
Uses
Used for the reconstitution of freeze-dried human plasma fractions
How to take
Sources & citations
- [1]Health Canada (DPD) · 01927930 · revised March 22, 2025
- [2]FDA DailyMed · 049cee29-7ec2-4d… · revised March 29, 2017 [PDF]
- [3]MHRA (UK) · PL106730023 · revised June 16, 2023
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.